ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO829

Targeting Pathologic Gβγ-GRK2 Signaling in CKD

Session Information

Category: CKD (Non-Dialysis)

  • 1903 CKD (Non-Dialysis): Mechanisms


  • Rudomanova, Valeriia, Cincinnati Children''s Hospital Medical Center, Cincinnati, Ohio, United States
  • Valiente-Alandi, Iñigo, Cincinnati Children''s Hospital Medical Center, Cincinnati, Ohio, United States
  • Ma, Qing, Cincinnati Children's Hospital, Cincinnati, Ohio, United States
  • Devarajan, Prasad, Cincinnati Children's Hospital, Cincinnati, Ohio, United States
  • Blaxall, Burns C., Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Chronic kidney disease (CKD) is a progressive deterioration of renal function characterized by replacement of functional renal parenchyma with fibrotic tissue. Our group recently reported the beneficial effects of attenuating Gβγ-G-protein coupled receptor kinase 2 (GRK2) signaling in the ischemia/reperfusion murine model of acute kidney injury (AKI). In this study, we tested the hypothesis that inhibiting Gβγ-GRK2 signaling might bestow a renoprotective effect in animal models of chronic kidney injury.


Research animals (C57Bl/6 10 week old male mice) were subjected to unilateral ischemia-reperfusion (UIR, 30min) or sham surgery followed by 14 days of reperfusion. The Gβγ-GRK2 small molecule inhibitor, Gallein, or Vehicle (PBS) were given once daily i.p. beginning 7 days after the injury and continued until sacrifice. GRK2 expression was also evaluated in human kidney biopsies and whole murine kidney lysates by RT-qPCR and Western blot.


We first identified a significant elevation of GRK2 mRNA (8 normal vs 10 dialysis, 1.9 fold increase, P=0.01) and protein (9 normal vs 10 dialysis, 20.6 fold increase, P=0.02) expression in biopsies obtained from dialysis patients vs normal human kidney biopsies. In the UIR model of CKD, GRK2 transcript expression positively correlated with Lipocalin 2 (NGAL) transcript, a clinically used renal injury marker (R squared=0.7488, P<0.0001). Small molecule inhibition of Gβγ-GRK2 significantly alleviated renal fibrosis as assessed by Picrosirius red staining (Sham, UIR+Vehicle, UIR+Gallein, n=8 per group, % fibrosis mean 1.422, 10.08, 4.665, respectively, P<0.0001), accompanied by a decline in NGAL gene expression.


Our results identify Gβγ-GRK2 signaling as a potential mediator of renal tubular injury and fibrosis and a promising target in CKD.

A: Pisrosirius Red staining (red color stains fibrotic areas); B: Hematoxilin & Eosin staining.


  • Other NIH Support